| Literature DB >> 25111308 |
Hong Xu1, Haiqing Li1, Jun Liu1, Dan Zhu1, Zhe Wang1, Anqing Chen1, Qiang Zhao1.
Abstract
A number of case-control studies have been conducted to clarify the association between ApoE polymorphisms and myocardial infarction (MI); however, the results are inconsistent. This meta-analysis was performed to clarify this issue using all the available evidence. Searching in PubMed retrieved all eligible articles. A total of 33 studies were included in this meta-analysis, including 18752 MI cases and 18963 controls. The pooled analysis based on all included studies showed that the MI patients had a decreased frequency of the ε2 allele (OR = 0.78, 95% CI = 0.70-0.87) and an increased frequency of the ε4 allele (OR = 1.15, 95% CI = 1.10-1.20); The results also showed a decreased susceptibility of MI in the ε2ε3 vs. ε3ε3 analysis (OR = 0.79, 95% CI = 0.68-0.90) and in the ε2 vs. ε3 analysis (OR = 0.78, 95% CI = 0.69-0.89), an increased susceptibility of MI in the ε3ε4 vs. ε3ε3 analysis (OR = 1.26, 95% CI = 1.12-1.41), in the ε4 vs. ε3 analysis (OR = 1.22, 95% CI = 1.12-1.32) and in the ε4ε4 vs. ε3ε3 analysis (OR = 1.59, 95% CI = 1.15-2.19). However, there were no significant associations among polymorphisms and MI for the following genetic models: frequency of the ε3 allele (OR = 0.99, 95% CI = 0.96-1.02); ε2ε2 vs. ε3ε3 analysis (OR = 0.73, 95% CI = 0.40-1.32); or ε2ε4 vs. ε3ε3 analysis (OR = 1.10, 95% CI = 0.99-1.21). Our results suggested that the ε4 allele of ApoE is a risk factor for the development of MI and the ε2 allele of ApoE is a protective factor in the development of MI.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25111308 PMCID: PMC4128680 DOI: 10.1371/journal.pone.0104608
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Flowchart of the study selection.
Detailed characteristics of studies included in this meta-analysis.
| Genotypes distribution (Cases/controls) | |||||||||||||||
| Study [Reference] | Year | Country | Ethnicity | Study | HWE | Total sample | ε2/ε2 | ε2/ε3 | ε3/ε3 | ε2/ε4 | ε3/ε4 | ε4/ε4 | ε2 | ε3 | ε4 |
| type | Case/Control | ||||||||||||||
| Utermann1984 | 1984 | Germany | Caucasion | HCC | Yes | 523/1031 | 7/120 | x68/124 | 333/617 | 11/15 | 92/236 | 12/29 | 86/359 | 493/977 | 115/280 |
| Cumming1984 | 1984 | Scotland | Caucasion | PCC | Yes | 239/400 | 0/2 | 18/51 | 128/233 | 10/11 | 77/99 | 6/4 | 28/64 | 223/383 | 93/114 |
| Lenzen1986 | 1986 | France | Caucasion | PCC | Yes | 570/624 | 1/6 | 50/67 | 360/393 | 10/20 | 137/125 | 12/13 | 61/93 | 547/585 | 159/158 |
| Eichner 1993 | 1993 | USA | Caucasion | PCC | Yes | 114/412 | 0/2 | 16/35 | 67/276 | 0/4 | 30/85 | 1/10 | 16/41 | 113/396 | 31/99 |
| Luc 1994 | 1994 | France | Caucasion | PCC | Yes | 574/680 | 3/6 | 54/92 | 352/428 | 14/14 | 133/126 | 18/14 | 71/112 | 539/646 | 165/154 |
| Hergenc 1995' | 1995 | Turkey | Caucasion | HCC | Yes | 50/60 | 0/0 | 7/6 | 41/47 | 0/2 | 2/5 | 0/0 | 7/8 | 50/58 | 2/7 |
| Kim 1995 | 1995 | Korea | Asian | HCC | Yes | 97/137 | 2/1 | 17/25 | 57/95 | 0/4 | 20/12 | 1/0 | 19/30 | 94/132 | 21/16 |
| Nakai 1998 | 1998 | Japan | Asian | PCC | Yes | 254/422 | 0/0 | 10/16 | 178/327 | 2/4 | 52/74 | 6/1 | 12/20 | 240/417 | 60/79 |
| Scaglione1999 | 1999 | Italy | Caucasion | HCC | No | 98/98 | NR | NR | NR | NR | NR | NR | 3/3 | 84/87 | 11/8 |
| Lambert 2000 | 2000 | France | Caucasion | PCC | Yes | 567/678 | 3/4 | 67/100 | 332/420 | 0/3 | 152/138 | 18/13 | 70/107 | 551/658 | 170/154 |
| Benes2000 | 2000 | Czech | Caucasion | PCC | Yes | 114/222 | 1/0 | 12/30 | 71/147 | 3/2 | 23/43 | 4/0 | 16/32 | 106/220 | 30/45 |
| Batalla 2000 | 2000 | Spain | Caucasion | PCC | Yes | 220/200 | 0/0 | 9/18 | 174/151 | 1/1 | 32/28 | 4/2 | 10/19 | 215/197 | 37/31 |
| Raslová 2001 | 2001 | Canada | Caucasion | PCC | Yes | 69/69 | 2/1 | 8/5 | 46/47 | 1/0 | 11/15 | 1/1 | 11/6 | 65/67 | 13/16 |
| Bai 2001 | 2001 | China | Asian | PCC | Yes | 47/50 | 0/0 | 4/5 | 40/39 | 0/0 | 6/3 | 0/0 | 4/5 | 50/47 | 6/3 |
| Freitas 2002 | 2002 | Australia | Caucasion | PCC | Yes | 411/624 | 3/4 | 24/67 | 254/372 | 9/15 | 111/147 | 10/19 | 36/86 | 389/586 | 130/181 |
| Mamotte 2002 | 2002 | Australia | Caucasion | PCC | Yes | 359/639 | 4/4 | 24/68 | 217/383 | 7/16 | 96/149 | 11/19 | 35/88 | 337/600 | 114/184 |
| Kolovou 2002 | 2002 | Greece | Caucasion | PCC | Yes | 124/240 | 0/0 | 3/34 | 94/159 | 0/5 | 27/40 | 0/2 | 3/39 | 124/233 | 27/47 |
| Keavney 2003 | 2003 | UK | Caucasion | PCC | Yes | 4487/5757 | NR | 440/686 | 2566/3384 | NR | 1206/1376 | NR | 440/686 | 4212/5446 | 1206/1376 |
| Kolovou 2003 | 2003 | Greece | Caucasion | PCC | Yes | 165/165 | 0/0 | 3/16 | 129/118 | 1/4 | 29/23 | 1/0 | 4/20 | 161/157 | 31/27 |
| Kumar 2003 | 2003 | India | Caucasion | PCC | Yes | 35/45 | 0/2 | 6/9 | 12/32 | 1/0 | 6/0 | 10/2 | 7/9 | 24/41 | 17/2 |
| Marques 2003 | 2003 | France | Caucasion | HCC | Yes | 400/338 | NR | NR | 272/228 | NR | NR | NR | 37/40 | 272/228 | 91/70 |
| Keavney 2004 | 2004 | UK | Caucasion | PCC | Yes | 4685/3460 | NR | 440/406 | 2566/1949 | 1206/810 | NR | NR | 1646/1216 | 3006/2355 | 1206/810 |
| Ranjith 2004 | 2004 | South Africa | Caucasion | PCC | Yes | 195/300 | 0/3 | 7/18 | 139/228 | 3/3 | 45/43 | 1/5 | 10/24 | 191/289 | 49/51 |
| Baum 2006 | 2006 | China | Asian | PCC | Yes | 231/331 | 0/2 | 13/60 | 164/203 | 4/6 | 46/39 | 4/1 | 17/68 | 223/302 | 54/46 |
| Aasvee 2006 | 2006 | Estonia | Caucasion | PCC | Yes | 71/85 | 1/1 | 4/13 | 45/52 | 2/3 | 16/16 | 3/0 | 7/17 | 65/81 | 21/19 |
| Koch 2008 | 2008 | Germany | Caucasion | PCC | Yes | 3657/1211 | 26/7 | 402/164 | 2279/736 | 63/23 | 809/263 | 78/18 | 491/194 | 3490/1163 | 950/304 |
| Kolovou 2009 | 2009 | Greece | Caucasion | PCC | Yes | 124/240 | NR | NR | NR | NR | NR | NR | 5/19 | 106/197 | 13/24 |
| Bahri 2008 | 2008 | Tunisia | Caucasion | PCC | Yes | 80/100 | 0/0 | 6/8 | 61/78 | 0/1 | 13/13 | 0/0 | 6/9 | 80/199 | 13/14 |
| Martinelli 2009 | 2009 | Italy | Caucasion | HCC | Yes | 394/287 | NR | NR | NR | NR | NR | NR | 34/25 | 285/220 | 76/42 |
| Al-Bustan 2009 | 2009 | Kuwaiti | Caucasion | HCC | No | 88/122 | 4/9 | 2/2 | 72/98 | 2/3 | 8/9 | 0/1 | 6/11 | 90/33 | 16/5 |
| Onrat 2012 | 2012 | Turkey | Caucasion | PCC | Yes | 36/100 | 0/0 | 12/4 | 72/27 | 0/0 | 16/4 | 0/1 | 12/4 | 100/35 | 16/5 |
| Tanguturi 2013 | 2013 | USA | Caucasion | HCC | Yes | 202/210 | 0/0 | 8/14 | 142/167 | 4/3 | 37/23 | 11/3 | 12/17 | 187/204 | 52/29 |
| Zende 2013 | 2013 | India | Caucasion | HCC | No | 150/150 | 6/7 | 13/16 | 59/85 | 7/4 | 22/14 | 43/24 | 26/27 | 94/115 | 72/42 |
HWE, Hardy-Weinberg equilibrium; NR, not reported; Cases, MI patients; HCC, hospital based case-control study; PCC, population based case-control study.
Figure 2Forest plot for ApoE gene polymorphism and MI risk in the ε2 allele frequency analysis.
Figure 3Forest plot for ApoE gene polymorphism and MI risk in the ε4 allele frequency analysis.
Results of meta-analysis of ApoE polymorphism and MI.
| Overall | Caucasion | Asian | ||||
| Analysis | OR (95% CI) | P/Phet | OR (95% CI) | P/Phet | OR (95% CI) | P/Phet |
|
| 0.73 (0.40–1.32) | 0.29/0.005 | 0.70 (0.38–1.31) | 0.27/0.004 | 1.07 (0.08–13.78) | 0.96/0.18 |
|
| 0.79 (0.68–0.90) | 0.001/0.001 | 0.80 (0.70–0.92) | 0.001/0.008 | 0.70 (0.31–1.60) | 0.84/0.007 |
|
| 1.10 (0.99–1.21) | 0.07/0.70 | 1.10 (1.00–1.21) | 0.05/0.63 | 0.66 (0.26–1.70) | 0.39/0.61 |
|
| 1.26 (1.12–1.41) | <0.001/0.001 | 1.23 (1.09–1.38) | 0.001/0.001 | 1.51 (1.14–2.00) | 0.004/0.39 |
|
| 1.59 (1.15–2.19) | 0.005/0.04 | 1.47 (1.07–2.02) | 0.02/0.05 | 6.95 (1.75–27.65) | 0.006/0.85 |
|
| 0.78 (0.69–0.89) | <0.001/0.04 | 0.80 (0.71–0.90) | <0.001/0.04 | 0.67 (0.37–1.23) | 0.20/0.22 |
|
| 1.22 (1.12–1.32) | <0.001/0.02 | 1.20 (1.10–1.30) | <0.001/0.02 | 1.49 (1.15–1.93) | 0.002/<0.001 |
|
| 0.78 (0.70–0.87) | <0.001/0.001 | 0.79 (0.71–0.88) | <0.001/0.005 | 0.65 (0.38–1.13) | 0.13/0.09 |
|
| 0.99 (0.96–1.02) | 0.38/1.00 | 0.99 (0.96–1.02) | 0.39/1.00 | 0.99 (0.86–1.13) | 0.22/0.94 |
|
| 1.15 (1.10–1.20) | 0.001/0.17 | 1.14 (1.09–1.19) | 0.001/0.18 | 1.47 (1.14–1.89) | 0.003/0.70 |
P, p value of the test on the association estimate; Phet, p value of the heterogeneity test.
Figure 4Cumulative meta-analysis of ApoE gene polymorphism and MI risk: A) ε2 allele frequency analysis; B) ε4 allele frequency analysis.
Figure 5Influence analysis of ApoE gene polymorphism and MI risk: A) ε2 allele frequency analysis; B) ε4 allele frequency analysis.
Figure 6Funnel plot of ApoE gene polymorphism and MI risk: A) ε2 allele frequency analysis; B) ε4 allele frequency analysis.